September 19, 2011
Bristol-Myers K.K. (BMKK) has applied for the additional indication of ovarian cancer progressing following anticancer chemotherapy for Vepesid Capsule (etoposide) and the additional indication of biliary tract cancer for Briplatin (cisplatin). Both applications are based on information in the public...read more